Abbvie Inc. | Date: 2016-11-21
Disclosed are compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of treating diseases during which NAMPT is expressed.
Abbvie Inc., Walter and Eliza Hall Institute of Medical Research | Date: 2017-01-04
Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.
Abbvie Inc. and Dana-Farber Cancer Institute | Date: 2017-01-11
Composition suitable for treating multiple myeloma in subject, comprising a therapeutically effective amount of HuLuc63, a therapeutically effective amount of lenalidomide and/or bortezomib, and a pharmaceutically acceptable carrier, wherein said composition is capable of being administered in a single or multiple dose regimen.
AbbVie B.V. and Abbvie Inc. | Date: 2017-03-22
The present invention relates spiro-cyclic amine derivatives of the formula (I)R1 is selected fromcyano,(2-4C)alkenyl, (2-4C)alkynyl, (1-4C)alkyl each optionally substituted with CN or one or more fluoro atoms,(3-6C)cycloalkyl, (4-6C)cycloalkenyl or a (8-10C)bicyclic group, each optionally substituted with halogen or (1-4C)alkyl,phenyl, biphenyl, naphthyl, each optionally substituted with one or more substituents independently selected from halogen, cyano, (1-6C)alkyl optionally substituted with one or more fluoro atoms, (1-6C)alkoxy optionally substituted with one or more fluoro atoms, amino, di(1-4C)alkylamino and (3-6C)cycloalkyl optionally substituted with phenyl which may be substituted with (1-4C)alkyl or halogen,phenyl substituted with phenoxy, benzyl, benzyloxy, phenylethyl or monocyclic heterocycle, each optionally substituted with (1-4C)alkyl optionally substituted with one or more fluoro atoms,monocyclic heterocycle optionally independently substituted with halogen, (1-6C)alkyl optionally substituted with one or more fluoro atoms, (3-6C)cycloalkyl, or phenyl optionally substituted with (1-4C)alkyl or halogen,andbicyclic heterocycle optionally substituted with halogen or (1-4C)alkyl optionally substituted with one or more fluoro atoms;-Y-(C_(n)-alkylene)-X- is a linking group whereinY is attached to R1 and selected from a bond, -O-, -CO-, -S-, -SO-, -SO_(2)-, -NH-, -CH=CH-, -C(CF_(3))=CH-, -CC-, -CH_(2)-O-, -O-CO-, -CO-O-, -CO-NH-, -NH-CO-, and trans-cyclopropylene;n is an integer from 0 to 10; andX is attached to the phenylene/pyridyl moiety and selected from a bond, -O-, -S-, -SO-, -SO_(2)-, -NH-, -CO-, -CH=CH-, and trans-cyclopropylene;R2 is H or independently selected from one or more substituents selected from halogen, (1-4C)alkoxy and (1-4C)alkyl optionally substituted with one or more fluor atoms; andR3 is (1-4C)alkylene-R4 wherein the alkylene group may be substituted with one or more halogen atoms or with (CH_(2))_(2) to form a cyclopropyl moiety, or R3 is (3-6C)cycloalkylene-R4, -CH_(2)-(3-6C)cycloalkylene-R4, (3-6C)cycloalkylene-CH_(2)-R4 or -CO-CH_(2)-R4, wherein R4 is -OH, -PO_(3)H_(2), -OPO_(3)H_(2), -COOH, -COO(1-4C)alkyl or tetrazol-5-yl;Q is a bond or -O-;-W-T- is selected from -CH=CH-, -CH_(2)-CH_(2)-, -CH_(2)-O-, -O-CH_(2)-, -O-CH_(2)-CH_(2)-, and -CO-O-;R5 is H or independently selected from one or more halogens;Z is CH, CR2 or N; andA represents a morpholine ring structure or a 5-, 6- or 7-membered cyclic amine;or a pharmaceutically acceptable salt, a solvate or hydrate thereof or one or more N-oxides thereof. The compounds of the invention have affinity to S1P receptors and may be used in the treatment, alleviation or prevention of diseases and conditions in which (a) S1P receptor(s) is (are) involved.
Abbvie Inc. and AbbVie Deutschland GmbH & Co. KG | Date: 2017-02-01
The present invention relates to a process for producing monolithic tablets. The method employs a melt-processed composition containing at least on active agent and at least one thermoplastic binder. The invention further relates to a method for cutting and deflashing a belt of pre-shaped bodies of a melt-processed composition, wherein the pre-shaped bodies are interconnected by flash.
Abbvie Inc. | Date: 2017-03-15
The application provides a syringe (100) acid a method for using the same. The syringe (100) includes a housing (200) having a reservoir (300) disposed therein and a plunger (400) to be received by the reservoir (300), the plunger (400) being moveable between a first plunger position and a second plunger position. The syringe (100) also includes a plunger spring (480) to urge the plunger (400) toward the second plunger position and an actuator (500) to deploy the plunger spring (480). The syringe (100) also includes a needle (600) proximate the distal end of the housing (200) displaceable from a first needle position to a second needle position, and a shroud (700) coupled with the housing (200). The shroud (700) is moveable between a retracted position and an extended position, the shroud (700) surrounding at least a portion Of the needle (600) when in the extended position.; The syringe (100) also includes an interlocking assembly (900), a shroud spring (800), and a locking assembly (1000) configured to inhibit movement of the shroud (700).
Abbvie Inc. | Date: 2017-04-05
The present application relates to 1,2,3,4)4a,5,6,7-octahydropyrazino[1,2-a][1,4]benzodiazepine, 1,2,3,4,4a,5,6,7-octahydropyrazino[1)2-a][1,5]benzodiazepine, 2,3,4,4a,5,6,7,11b-octahydro-1H-pyrido[3,4-d(]benzazepine, 1,2,3,4,4a,5,6,7- octahydropyrazino[1,2-a]benzazepine, 1,2,3,4,4a,5-hexahydro-7H-pyrazino[1,2-a][4,1]benzoxazepine, and 2,3,4,4a,5,6-hexahydro-1H-pyrazino[2,1-d][1,5]benzoxazepine, and 5,6,7,7a,8,9,10,11-octahydropyrazino[1,2-d]pyrido[3,2-6] [1,4]diazepine derivatives of formula (I) wherein R^(1), R^(2), R^(3), R^(4), R^(5), R^(6), X^(1), X^(2), X^(3), X^(4), Y^(1), Y^(2), and Y^(3) are as defined in the specification. The present application also relates to compositions comprising such compounds, and methods of treating disease conditions using such compounds and compositions, and methods for identifying such compounds.
Abbvie Inc. | Date: 2017-02-08
The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.
Abbvie Inc. and Apogenix | Date: 2017-03-01
Provided herein are specific TRAIL receptor agonist proteins, nucleic acids encoding the same, and methods of treating a subject having a TRAIL-associated disease or disorder. The TRAIL receptor agonist proteins provided herein comprise three soluble TRAIL domains and an Fc fragment. The TRAIL receptor agonist proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications.
Abbvie Inc. | Date: 2017-01-18
The present invention pertains to derivatives of tylosin A. In particular, the present invention pertains to compounds having a structure of Formula (I). The present invention also pertains to compositions comprising derivatives of tylosin A and methods of treating or preventing conditions or disorders using such compounds and compositions.